Please use this identifier to cite or link to this item:
|Title:||The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer||Authors:||Aribi, A.
|Issue Date:||15-Jun-2013||Citation:||Aribi, A., Gery, S., Lee, D.H., Thoennissen, N.H., Thoennissen, G.B., Alvarez, R., Ho, Q., Lee, K., Doan, N.B., Chan, K.T., Toh, M., Said, J.W., Koeffler, H.P. (2013-06-15). The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer. International Journal of Cancer 132 (12) : 2730-2737. ScholarBank@NUS Repository. https://doi.org/10.1002/ijc.27950||Abstract:||Despite recent advances in therapy, breast cancer remains the second most common cause of death from malignancy in women. Chemotherapy plays a major role in breast cancer management, and combining chemotherapeutic agents with nonchemotherapeutic agents is of considerable clinical interest. Cucurbitacins are triterpenes compounds found in plants of the Cucurbitaceae family, reported to have anticancer and anti-inflammatory activities. Previously, we have shown antiproliferative activity of cucurbitacin B (CuB) in breast cancer, and we hypothesized that combining CuB with chemotherapeutic agents can augment their antitumor effect. Here, we show that a combination of CuB with either docetaxel (DOC) or gemcitabine (GEM) synergistically inhibited the proliferation of MDA-MB-231 breast cancer cells in vitro. This antiproliferative effect was accompanied by an increase in apoptosis rates. Furthermore, in vivo treatment of human breast cancer orthotopic xenografts in immunodeficient mice with CuB at either low (0.5 mg/kg) or high (1 mg/kg) doses in combination with either DOC (20 mg/kg) or GEM (12.5mg/kg) significantly reduced tumor volume as compared with monotherapy of each drug. Importantly, no significant toxicity was noted with low-dose CuB in combination with either DOC or GEM. In conclusion, combination of CuB at a relatively low concentration with either of the chemotherapeutic agents, DOC or GEM, shows prominent antiproliferative activity against breast cancer cells without increased toxicity. This promising combination should be examined in therapeutic trials of breast cancer. Copyright © 2012 UICC.||Source Title:||International Journal of Cancer||URI:||http://scholarbank.nus.edu.sg/handle/10635/126869||ISSN:||00207136||DOI:||10.1002/ijc.27950|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Oct 13, 2021
WEB OF SCIENCETM
checked on Oct 13, 2021
checked on Oct 14, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.